Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Utility of suPAR and NGAL for AKI Risk Stratification and Early Optimization of Renal Risk Medications among Older Patients in the Emergency Department

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Social Distancing Policies in the Coronavirus Battle: A Comparison of Denmark and Sweden

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Adaptations and modifications to a co-designed intervention and its clinical implementation: a qualitative study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Diagnosis of acute kidney injury (AKI) based on plasma creatinine often lags behind actual changes in renal function. Here, we investigated early detection of AKI using the plasma soluble urokinase plasminogen activator receptor (suPAR) and neutrophil gelatinase-sssociated lipocalin (NGAL) and observed the impact of early detection on prescribing recommendations for renally-eliminated medications. This study is a secondary analysis of data from the DISABLMENT cohort on acutely admitted older (≥65 years) medical patients (n = 339). Presence of AKI according to kidney disease: improving global outcomes (KDIGO) criteria was identified from inclusion to 48 h after inclusion. Discriminatory power of suPAR and NGAL was determined by receiver-operating characteristic (ROC). Selected medications that are contraindicated in AKI were identified in Renbase®. A total of 33 (9.7%) patients developed AKI. Discriminatory power for suPAR and NGAL was 0.69 and 0.78, respectively, at a cutoff of 4.26 ng/mL and 139.5 ng/mL, respectively. The interaction of suPAR and NGAL yielded a discriminatory power of 0.80, which was significantly higher than for suPAR alone (p = 0.0059). Among patients with AKI, 22 (60.6%) used at least one medication that should be avoided in AKI. Overall, suPAR and NGAL levels were independently associated with incident AKI and their combination yielded excellent discriminatory power for risk determination of AKI.

Original languageEnglish
Article number843
JournalPharmaceuticals (Basel, Switzerland)
Volume14
Issue number9
ISSN1424-8247
DOIs
Publication statusPublished - 25 Aug 2021

    Research areas

  • Acute kidney injury, Early biomarker, Emergency department, Medication optimization, Older patients, Plasma neutrophil gelatinase‐associated lipocalin, Soluble urokinase plasminogen activator receptor

ID: 67889504